Skip to main content
Skip to main content
NMTC logo

NeuroOne Medical Technologies Corporation (NMTC) Stock Analysis

$2.16 -$0.18 (-7.69%) |Avoid · 21
Signals are mixed — the Council read leans Split View (41/100) while the AI fundamental score is 21/100 (grade F); the two lenses disagree, so weigh the breakdown below. Strongest signal: Ray Dalio bullish · Biggest watch-out: Seth Klarman bearish.
MCap: $18.8M| Vol: 50.1K|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

NeuroOne Medical Technologies Corporation (NMTC) trades at $2.16 with AI Score 21/100 (Grade F). NeuroOne Medical Technologies Corporation is a medical technology company focused on developing and commercializing thin film electrode technology for neurological disorders. Market cap: $18.8M, Sector: Healthcare.

Price as of Jul 20, 2026 · Last analyzed: May 10, 2026
NeuroOne Medical Technologies Corporation is a medical technology company focused on developing and commercializing thin film electrode technology for neurological disorders. They have a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator.

Analyst Coverage for NMTC: NMTC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NMTC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.

Watch the NMTC film Every key number, told as a short cinematic story — just press play. ~2 min
Council Score · Weighted Average of 3 Disciplines
Split View 41/100 · C

NMTC: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.

How is this calculated? →
MoonshotScore · Growth Potential · 21/100
Business Quality
Weak Is this a genuinely good business?
Financial Safety
Neutral Could this blow up on me?
Valuation
Weak Am I paying a fair price?
Growth Durability
Moderate Is the growth real and likely to last?
Momentum
Negative Is the market already moving on this?
Legends Council · 5 Legends + Moon AI
Ray Dalio
Bullish
Ken Griffin
Neutral
Jim Simons
Neutral
Izzy Englander
Bullish
Seth Klarman
Bearish
Moon AI
Neutral
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Neutral
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →

Why this analysis is different

  • A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
  • An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
  • Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

NeuroOne Medical Technologies Corporation (NMTC) Healthcare & Pipeline Overview

CEODavid A. Rosa
Employees17
HeadquartersEden Prairie, MN, US
IPO Year2018

NeuroOne Medical Technologies Corporation, a medical device company, specializes in thin film electrode technology for treating neurological disorders. Their focus on cEEG, sEEG, spinal cord stimulation, brain stimulation, and ablation solutions, coupled with a partnership with RBC Medical Innovations, positions them in the neuromodulation market.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: May 10, 2026

What Is the Investment Thesis for NMTC?

As of May 10, 2026 — figures reflect the data available on that date.

NeuroOne Medical Technologies Corporation presents a speculative investment opportunity within the neuromodulation market. The company's focus on thin film electrode technology for various neurological applications, including epilepsy and Parkinson's disease, positions it in a high-growth area. A key value driver is the strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. Upcoming catalysts include regulatory milestones for its sEEG and ablation products. However, potential risks include the company's small market capitalization of $18.8M, negative profit margin of -78.3%, and the challenges inherent in bringing novel medical devices to market. Successful commercialization and regulatory approvals are critical for realizing the company's potential.

Based on FMP financials and quantitative analysis

NMTC Key Highlights

  • Market capitalization of $18.8M indicates a small-cap company with potential for high growth but also higher risk.
  • Gross margin of 54.9% suggests strong pricing power for its products, but needs to be balanced against high operating expenses.
  • Profit margin of -78.3% reflects significant ongoing investments in R&D and commercialization efforts.
  • Beta of 0.58 indicates lower volatility compared to the overall market.
  • Strategic partnership with RBC Medical Innovations provides access to complementary technologies and expertise.

Who Are NMTC's Competitors?

NMTC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
ABT Abbott Laboratories $101.72 +1.03% $177B 72
BSX Boston Scientific Corporation $43.77 -0.59% $65.1B 75
LHDX Lucira Health, Inc. $0.45 +0.00% $18.4M 64
PYNKF Perimeter Medical Imaging AI, Inc. $0.22 +2.14% $20.9M 73
PLSM PLSM $3.51 -8.12% $22.8M 60
VPTDF VentriPoint Diagnostics Ltd. $0.08 -0.24% $15.4M 62
CNVIF Conavi Medical Corp. $0.16 +1.71% $13.7M 66
NVYTF Novacyt S.A. $0.48 -0.00% $34.8M 61

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NMTC's Key Strengths?

  • Proprietary thin film electrode technology.
  • Strategic partnership with RBC Medical Innovations.
  • Focus on high-growth neuromodulation market.
  • Potential for disruptive innovation in electrode technology.

What Are NMTC's Weaknesses?

  • Small market capitalization and limited financial resources.
  • Negative profit margin and reliance on external funding.
  • Dependence on regulatory approvals for product commercialization.
  • Limited commercial track record.

What Could Drive NMTC Stock Higher?

  • FDA clearance for sEEG electrode technology.
  • Completion of development for radio frequency ablation generator with RBC Medical Innovations.
  • Expansion of clinical studies to demonstrate the efficacy of NeuroOne's technology.
  • Pursuit of strategic partnerships for expanded market access.

What Are the Key Risks for NMTC?

  • Financial-distress signal — its Altman Z-Score of -10.39 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-98.3%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
  • Delays in regulatory approvals for key products.
  • Competition from established players in the neuromodulation market.
  • Dependence on external funding to support operations and R&D.
  • Technological obsolescence of existing products.
  • Risks associated with commercializing new medical devices.

What Are the Growth Opportunities for NMTC?

  • Expanding applications of thin film electrode technology: NeuroOne can leverage its core technology to develop new applications beyond its current focus areas, such as treating other neurological disorders or exploring new therapeutic modalities. The market for neuromodulation therapies is expanding, driven by technological advancements and increasing demand for minimally invasive treatments. This expansion provides NeuroOne with opportunities to diversify its product portfolio and address a wider range of patient needs, potentially leading to increased revenue streams and market share.
  • Strategic partnerships and collaborations: NeuroOne can pursue additional partnerships with medical device companies, research institutions, or pharmaceutical companies to accelerate product development, expand its market reach, and access new technologies. Collaborations can provide access to complementary expertise, resources, and distribution channels, enabling NeuroOne to bring its products to market more efficiently and effectively. These partnerships can also enhance the company's credibility and attract further investment.
  • Geographic expansion into international markets: NeuroOne can expand its sales and marketing efforts into international markets, particularly in Europe and Asia, where there is a growing demand for advanced neuromodulation therapies. International expansion requires navigating regulatory hurdles and establishing distribution networks, but it can significantly increase NeuroOne's revenue potential and reduce its reliance on the US market. Thorough market research and strategic partnerships are crucial for successful international expansion.
  • Development of next-generation electrode technology: NeuroOne can invest in research and development to develop next-generation electrode technology with improved performance, biocompatibility, and functionality. Advancements in materials science and microfabrication techniques can lead to electrodes with enhanced signal quality, reduced invasiveness, and longer lifespan. These improvements can differentiate NeuroOne's products from competitors and attract a larger customer base. Continuous innovation is essential for maintaining a competitive edge in the rapidly evolving medical device industry.
  • Securing regulatory approvals for new products: NeuroOne's growth is heavily dependent on obtaining regulatory approvals from the FDA and other regulatory agencies for its sEEG and ablation products. Successful regulatory approvals will allow the company to commercialize its products and generate revenue. Streamlining the regulatory approval process and building strong relationships with regulatory agencies are crucial for accelerating product development and minimizing delays. A clear regulatory strategy and robust clinical data are essential for securing timely approvals.

What Opportunities Does NMTC Have?

  • Expanding applications of thin film electrode technology.
  • Geographic expansion into international markets.
  • Development of next-generation electrode technology.
  • Strategic partnerships and collaborations.

What Threats Does NMTC Face?

  • Competition from larger, established medical device companies.
  • Regulatory hurdles and delays in product approvals.
  • Technological obsolescence.
  • Economic downturns impacting healthcare spending.

What Are NMTC's Competitive Advantages?

  • Proprietary thin film electrode technology.
  • Strategic partnership with RBC Medical Innovations.
  • Focus on specialized applications in neuromodulation.
  • Intellectual property protection through patents and trade secrets.

What Does NMTC Do?

NeuroOne Medical Technologies Corporation, founded to address unmet needs in neurological disorder treatment, operates as a medical technology company focused on the development and commercialization of innovative electrode technology. The company's core expertise lies in thin film electrode technology, which is utilized in a range of applications including continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions. These solutions target patients suffering from conditions such as epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain. NeuroOne's technology aims to improve the precision and efficacy of neurological interventions. A key strategic partnership with RBC Medical Innovations is focused on developing a radio frequency ablation generator, designed for use with NeuroOne's combination recording and ablation electrode. This collaboration seeks to streamline procedures by enabling simultaneous brain activity recording and tissue ablation using a single electrode. Headquartered in Eden Prairie, Minnesota, NeuroOne is dedicated to advancing the field of neuromodulation through its innovative technology and strategic partnerships.

What Products and Services Does NMTC Offer?

  • Develops thin film electrode technology for medical applications.
  • Focuses on solutions for continuous electroencephalogram (cEEG) recording.
  • Provides technology for stereoelectroencephalography (sEEG) recording.
  • Offers solutions for spinal cord stimulation.
  • Develops technology for brain stimulation.
  • Creates ablation solutions for neurological disorders.

How Does NMTC Make Money?

  • Develops and manufactures thin film electrodes.
  • Partners with RBC Medical Innovations for radio frequency ablation generator development.
  • Seeks regulatory approvals for its medical devices.
  • Commercializes its products through direct sales and distribution networks.

What Industry Does NMTC Operate In?

NeuroOne Medical Technologies Corporation operates within the medical device industry, specifically targeting the neuromodulation market. This market is experiencing growth driven by an aging population and increasing prevalence of neurological disorders. The competitive landscape includes larger, established players as well as smaller, innovative companies. NeuroOne's focus on thin film electrode technology and its partnership with RBC Medical Innovations differentiate it from competitors.

Who Are NMTC's Key Customers?

  • Hospitals and medical centers.
  • Neurosurgeons and neurologists.
  • Patients suffering from epilepsy and other neurological disorders.
  • Research institutions conducting neurological studies.
AI Confidence: 71% Updated: May 10, 2026

How NeuroOne Medical Technologies Corporation Is Valued

NeuroOne Medical Technologies Corporation carries a market capitalization of $18.8M, placing it in the micro-cap category. Relative to its peer group, NMTC's quantitative score of 21/100 is below the peer average of 69/100.

ROE -98%Key Financial Metrics

Return on equity for NeuroOne Medical Technologies Corporation stands at -98.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -84.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -29.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.37 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -26.3%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

NeuroOne Medical Technologies Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -10.39 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project NeuroOne Medical Technologies Corporation revenue of about $10.7M for fiscal 2026, with EPS near $-1.28. The estimate reflects 3 contributing analysts.

NMTC Financials

Fundamental Snapshot

Revenue Growth (FY)
+250.4%
Net Income Growth (FY)
+70.7%
EPS Growth (FY)
+80.4%
Free Cash Flow Growth (FY)
+73.8%
Return on Equity (TTM)
-98.3%
Current Ratio
4.4

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Recent insider buying indicates strong confidence in the company's future prospects, suggesting that key stakeholders believe in the value of their innovations.
  • Community sentiment has shifted positively as discussions around NeuroOne's potential breakthroughs in neuromodulation technologies have gained traction.
  • The company's recent partnerships with medical institutions highlight its commitment to expanding market reach and validating its technology.
  • Increased media coverage and positive reviews of NeuroOne's products have bolstered public interest and investor enthusiasm.

Bear Case

  • Concerns about regulatory hurdles in the medical technology sector could pose challenges for NeuroOne's product approvals and market entry.
  • Some community members express skepticism regarding the scalability of NeuroOne's technology, questioning whether it can achieve widespread adoption.
  • Recent market volatility has led to cautious sentiment among investors, with some wary of investing in smaller medical tech firms amid economic uncertainty.
  • Inconsistent communication from the company regarding product timelines has raised doubts among investors about execution and transparency.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

NMTC Latest News

NMTC Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NMTC.

Price Targets

Wall Street price target analysis for NMTC.

NMTC MoonshotScore

21/100

What does this score mean?

The MoonshotScore rates NMTC 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.

Leadership: David A. Rosa

CEO

David A. Rosa serves as the CEO of NeuroOne Medical Technologies Corporation. His background includes experience in the medical device industry, with a focus on commercialization and strategic partnerships. He has a proven track record of leading teams and driving growth in emerging medical technology companies. His expertise spans product development, regulatory affairs, and market access. He is responsible for overseeing the company's strategic direction and execution.

Track Record: Under David A. Rosa's leadership, NeuroOne Medical Technologies Corporation has focused on advancing its thin film electrode technology and securing strategic partnerships, notably with RBC Medical Innovations. He has overseen the company's efforts to obtain regulatory approvals for its sEEG and ablation products. His leadership is focused on driving the company towards commercialization and establishing a strong market presence.

NMTC Healthcare Stock FAQ

What does the AI Score mean for NMTC?

NMTC holds an AI Score of 21/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. NeuroOne Medical Technologies Corporation is a medical technology company focused on developing and commercializing thin film electrode technology for neurological disorders. They have a strategic …

What does NeuroOne Medical Technologies Corporation do?

NeuroOne Medical Technologies Corporation is a medical technology company specializing in the development and commercialization of thin film electrode technology. These electrodes are designed for use in various neurological applications, including continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions.

What do analysts say about NMTC stock?

Analyst coverage of NeuroOne Medical Technologies Corporation (NMTC) is limited, reflecting its small-cap status and early stage of commercialization. Key valuation metrics are influenced by the company's negative profit margin and ongoing investments in R&D. Growth considerations center on the successful regulatory approval and commercial launch of its sEEG and ablation products.

What are the main risks for NMTC?

NeuroOne Medical Technologies Corporation faces several key risks common to early-stage medical device companies. These include the risk of delays in obtaining regulatory approvals from the FDA for its sEEG and ablation products, which could significantly impact its commercialization timeline. Competition from larger, established players in the neuromodulation market poses another challenge.

What are the key factors to evaluate for NMTC?

NeuroOne Medical Technologies Corporation (NMTC) holds an AI score of 21/100 (low). Not financial advice.

How frequently does NMTC data refresh on this page?

NMTC's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.

What has driven NMTC's recent stock price performance?

NeuroOne Medical Technologies Corporation (NMTC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary thin film electrode technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider NMTC overvalued or undervalued right now?

NeuroOne Medical Technologies Corporation (NMTC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research NMTC before investing?

Before investing in NeuroOne Medical Technologies Corporation (NMTC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on publicly available sources and may be subject to change.
  • Financial data is as of the last reported period.
  • Analyst opinions may vary.
Data Sources

Popular Stocks